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Abstract: Reverse transcriptase (RT) is a viral enzyme crucial for HIV-1 replication. Currently, 12 drugs are targeted against the 
RT. The low fidelity of the RT-mediated transcription leads to the quick accumulation of drug-resistance mutations. The sequence-
resistance relationship remains only partially understood. Using publicly available data collected from over 15 years of HIV proteome 
research, we have created a general and predictive rule-based model of HIV-1 resistance to eight RT inhibitors. Our rough set-based 
model considers changes in the physicochemical properties of a mutated sequence as compared to the wild-type strain. Thanks to the 
application of the Monte Carlo feature selection method, the model takes into account only the properties that significantly contribute 
to the resistance phenomenon. The obtained results show that drug-resistance is determined in more complex way than believed. 
We confirmed the importance of many resistance-associated sites, found some sites to be less relevant than formerly postulated and—
more importantly—identified several previously neglected sites as potentially relevant. By mapping some of the newly discovered 
sites on the 3D structure of the RT, we were able to suggest possible molecular-mechanisms of drug-resistance. Importantly, our model 
has the ability to generalize predictions to the previously unseen cases. The study is an example of how computational biology methods 
can increase our understanding of the HIV-1 resistome.
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Introduction
More than two decades have passed since the discovery 
of  HIV,  the  causative  agent  of  AIDS.  Numerous 
groups focused their research on understanding the 
details of HIV life cycle and on developing efficient 
antiviral  therapies.  Unfortunately,  the  high  rate  of 
replication combined with the high mutability of the 
virus leads to the rapid emergence of drug-resistant 
strains efficiently undermining the efforts to stop the 
AIDS pandemic. Currently, there are some 7,000 new 
HIV infections reported worldwide every day. In total, 
more than 30 million people in both the developed 
and the developing countries are HIV-positive.1 About 
109  virions  are  produced  in  an  infected  individual 
every day and it has been estimated that each possible 
single-point  mutation  arises  104–105 times  in  this 
population.2  While  some  mutations  result  in  the 
production  of  functionally-impaired  viruses,  other 
lead to the emergence of drug-resistant forms.
Reverse  transcriptase  (RT)  is  one  of  the  viral 
enzymes that are required for successful replication. 
The  RT  catalyzes  reverse  transcription,  a  process 
of  transforming  single-stranded  viral  RNA  into 
double-stranded viral DNA. The viral DNA is later 
incorporated into the host genome and it re-programs 
the  host  cell  to  produce  new  viral  particles  that 
undergo maturation, bud off and infect new cells thus 
completing the viral life-cycle. In peripheral blood 
lymphocytes the maturation occurs after viral release 
while  in  macrophages  it  takes  place  prior  to  the 
release, within the cell, in the multivesicular bodies. 
Not unlike the other enzymes in the family of reverse 
transcriptases,  the  HIV-1  RT  lacks  proof-reading 
activity which, combined with the high replication 
rate of the virus and the RT-mediated recombination, 
leads to the rapid emergence of HIV mutants. Many 
of  these  mutants  are  drug-resistant.  The  first  anti-
viral therapies were targeted against the RT and this 
enzyme still remains one of the most common targets 
for anti-HIV drugs. An initial hope that followed the 
introduction of AZT (Zidovudine), the first anti-viral 
agent targeting HIV, has been quickly shattered by 
the rapid emergence of drug-resistant viruses. Among 
the 25 drugs currently used in HIV therapy, 12 attempt 
at inhibiting the RT enzyme.
There exist two groups of RT inhibitors, namely the 
nucleoside/nucleotide RT inhibitors (NRTI) and the 
non-nucleoside RT inhibitors (NNRTI). The former 
ones mimic dNTPs, the ordinary RT substrates but 
due to the lack of the 3’-OH group in the ribose ring 
they inhibit DNA chain elongation immediately after 
being incorporated. The mode of action of the NNRTI 
drugs is somewhat different since they bind in the 
so-called NNRTI-binding pocket of the RT and induce 
conformational changes that terminate the synthesis 
of the viral DNA.
Various  attempts  have  been  undertaken  to 
associate  particular  mutations  in  the  RT  sequence 
with  the  drug  resistance  level.  Often,  however,  it 
is  not  a  single  mutation,  but  rather  a  non-linear 
combination  of  different  mutations  that  leads  to 
drug resistance. This increases the complexity of the 
problem  and  various  machine  learning  techniques 
have been used in order to predict resistance from 
RT sequence. Drăghici and Potter3 have used neural 
networks to build a predictive model of HIV drug 
resistance  to  RT  inhibitors.  The  commonly  used 
Geno2Pheno  tool4  relates  sequence  to  resistance 
by using regression models. An international panel 
of experts semiannually releases a set of rules for 
predicting  resistance.5  Similar  approach  has  been 
used by Johnson et al6 Garriga and Menéndez-Arias7 
released a tool that uses the available sets of expert-
derived rules to predict resistance. In their interesting 
studies,  Rhee  et al8  use  five  different  statistical 
learning methods (decision trees, neural networks, 
support vector regression, least-squares regression and 
least-angle regression) to model sequence-resistance 
relationship  in  HIV-1.  A  fresh  and  stimulating 
approach to the problem is presented in Kjaer et al9 
where  the  authors  propose  to  represent  protein 
sequences  in  terms  of  physicochemical  properties 
of amino acids. Recently, Prosperi et al10 published 
an interesting comparison of linear and non-linear 
machine learning techniques used in HIV resistome 
research.  They  conclude  that  fully  data-driven 
models derived from large-scale data are promising 
as  antiretroviral  treatment  decision  support  tools 
and  postulate  complementing  sequence  data  sets 
with patient-derived data such as treatment history.
Although the existing models were able to predict 
HIV-1  resistance  to  RT  inhibitors,  none  of  them 
provided  any  deeper  insight  into  the  underlying 
mechanisms in a physicochemical sense. There was 
also a lack of a method that would be able to predict 
resistance caused by a previously unseen mutation. rough set-based model of hIV-1 rT resistome
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In  this  paper  we  attempted  at  filling  this  gap  by 
developing a computational model of HIV-1 resistance 
to  several  RT  inhibitors.  Rather  than  looking  at 
mutating amino acids, we based our model on local 
physicochemical  properties  of  a  protein  sequence. 
This approach, combined with the Monte Carlo feature 
selection  and  the  rough  set  theory  resulted  in  an 
interpretable high quality model of the RT resistome. The 
model consists of a number of general IF-THEN rules 
associating changes in the physicochemical properties 
of RT-sequence with drug resistance level, e.g.:
 IF(polarityatsite101=(-∞, 2.100))
  AND (normalized freq. of turn at site 
190= [0.045, ∞])
THEN resistant to Nevirapine
This  makes  the  model  easy-to-interpret  and 
generative  and  lets  us  believe  that  the  presented 
approach will contribute to the development of new, 
more potent antiretroviral drugs.
Materials and Methods
Data
We  used  publicly  available  data  obtained  from 
Stanford HIV Drug Resistance Database.8 For each 
of  the  examined  drugs  we  extracted  a  number  of 
amino acid sequences of the HIV-1 RT p66 subunit. 
Each sequence in the database has been annotated 
with the resistance value relative to the HXB2 wild-
type  strain.  Since  Zhang  et al11  have  demonstrated 
that  the  Monograms  PhenoSense  is  more  reliable 
than other drug-resistance-testing assays and that it 
produces highly reproducible results, we used only 
the sequences with the resistance value determined 
using this method. In total, there were 781 sequences 
of the p66 subunit (91% of them complete within the 
first 240 aa sites, 31% of them complete within all the 
560 aa sites) that we could use for constructing data 
sets. Following the established clinical practice, we 
labeled each sequence as “susceptible”, “moderately 
resistant” or “resistant”. We used cut-off values for 
the  discretization  as  described  in  Rhee  et al.8  The 
detailed  distributions  of  the  resistance  classes  per 
drug are presented in Table 1.
Description of sequences
Kjaer et al9 have used 544 different physicochemical 
properties of amino acids obtained from the aaIndex 
database12  to  describe  HIV-1  protein  sequences. 
Although  we  used  the  descriptors  from  the  same 
database,  our  approach  is  different.  Rather  than 
constructing a large number of data sets, each based 
on a single physicochemical property, we constructed 
one data set per each antiviral drug and described each 
amino acid in a sequence by a vector of biologically 
relevant  and  interpretable  properties.  Following 
procedure described by Rudnicki and Komorowski,13 
we  extracted  a  number  of  biologically-meaningful 
descriptors from the aaIndex database.
First, we selected descriptors that are representative 
for three broad biophysical categories:
1. Transfer free energy from octanol to water14 for 
hydrophobicity;
Table 1. Number of resistance-annotated sequence examples per class.
class Drug number of examples Total
Training set Test set
susceptible Moderately 
resistant
Resistant Total susceptible Moderately 
resistant
Resistant Total
nrTI Abacavir 159 257 150 566 39 64 37 140 706
Didanosine 271 256 40 567 67 63 9 139 706
Lamivudine 172 95 307 574 42 23 76 141 715
stavudine 295 182 89 566 73 45 22 140 706
Tenofovir 183 61 31 276 46 15 7 68 344
Zidovudine 274 143 147 564 68 35 36 139 703
nnrTI Delavirdine 352 95 132 579 87 23 33 143 722
nevirapine 316 43 240 599 79 10 59 148 747Kierczak et al
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2. Normalized van der Waals volume15 for size;
3. Isoelectric point16 for charge.
These properties were fixed during the simulated 
annealing run. Than we added randomly four different 
properties and computed the sum of the r-square for all 
pairs of this set, which was used as a pseudo-energy 
measure. A single move in the simulation consisted 
of  replacing  one  of  the  four  random  properties. 
Moves leading to the decrease of pseudo-energy were 
always accepted, and moves leading to the increase of 
pseudo-energy were accepted with the probability:
p = exp(-DE/(kT))
where DE is the the increase of pseudo-energy, T is a 
pseudo-temperature and k is a scaling constant. The 
pseudo-temperature  was  slowly  decreasing  during 
simulation, from 1000 to 1, and the scaling constant 
was  selected  by  trial  and  error.  Ultimately,  we 
selected seven relatively low-correlated (cf. Fig. 1) 
physicochemical  descriptors  that  are  presented  in 
Table 2.
The  selected  properties  let  us  represent  each 
naturally  occurring  amino  acid  as  a  unique  point 
in  the  coordinates  frame  spanned  by  them.  After 
the  description,  each  amino  acid  sequence  in 
the  data  set  was  represented  by  3,920  properties 
(560 aa × 7 properties). We described each site in 
an aa sequence as a difference between the vector 
representing the wild-type and the vector representing 
the observed amino acid. Therefore, if no mutation 
was  observed  at  all,  the  site  was  described  by 
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Figure 1. Correlation matrix of physicochemical descriptors. The lower triangle contains bivariate scatter plots with a fitted line. The actual absolute values of the 
correlation are provided. The significance levels of the correlation are encoded in the following way: p = 0.001(***); p = 0.01(**); p = 0.05(*); p = 0.1(.).rough set-based model of hIV-1 rT resistome
Bioinformatics and Biology Insights 2009:3  113
the vector of seven zeroes. The final data sets were 
the ensembles of the described sequences annotated 
with the drug resistance values.
Monte Carlo feature selection
In order to select only the attributes (here the properties 
of 560 amino acids) that significantly contributed 
to drug resistance, we applied Monte Carlo Feature 
Selection (MCFS) method as described in Dramiński 
et al.21 In short, MCFS relies on the construction 
of  a  large  number  of  decision  trees.  Trees  are 
trained  on  different  random  subsets  of  attributes 
and  different  random  subsets  of  objects.  More 
precisely, out of all d features, we select s random 
subsets of m features, s and m being fixed, s being 
large and m  d, and for each subset of features, 
t  trees  are  constructed  and  their  performance  is 
assessed. Each of the t trees in the inner loop is 
trained  and  evaluated  on  a  different,  randomly 
selected training and test data sets. The evaluation 
results obtained from all s.t trees let one build a 
ranking  of  features  reflecting  their  importance 
or,  in  other  words,  their  discriminative  power. 
In  due  course,  the  most  informative  features  are 
selected with the help of a Student’s t-test.
In  this  way,  all  non-informative  features  were 
removed  from  the  initial  data  set.  The  results 
of  the  feature  selection  are  presented  in  tables: 
Table 3–Table 10. 
For  the  sake  of  comparison,  the  process  of 
attributes-ranking differs between Breiman’s random 
forests  (RF)22  and  MCFS.  In  RF,  the  ranking  is 
obtained by reshuffling the values of an attribute and 
observing the change in the quality of classification. 
In MCFS randomization test is done in a standard 
way by reshuffling decision labels. The importance of 
an attribute is determined by looking at the weighted 
accuracy  related  to  randomization  test-derived 
background. Another  important  difference  between 
MCFS and RF is that while in the former individual 
trees  are  built  on  training  samples  drawn  without 
replacement  from  the  original  set  of  samples  (and 
are evaluated on the remaining samples) in the latter 
bootstrap techniques are used which rely on sampling 
with replacement.
We perform feature selection on the whole entire 
data sets prior to splitting them into the training set 
and the test set. In our previous work,21 we argue in 
detail and show by examples that the MCFS provides 
a possibly objective ranking of features, independent 
of a classifier to be later used and pertaining only to 
the classification problem per se. In particular, using 
the MCFS does not lead to overfitting when proper 
classification  is  performed.  At  the  same  time,  to 
benefit the most from the application of the MCFS, 
it should be performed on the largest available set of 
examples.
rough sets
Rough  set  theory  described  in  Pawlak23  has  been 
introduced  in  the  early  eighties.  It  constitutes  a 
mathematical  framework  particularly  suitable  for 
dealing with imprecise and incomplete data. In the 
rough set-based machine learning a set of minimal 
decision IF-THEN rules is inferred from a number 
of labelled examples. These rules constitute a model 
that  can  be  used  for  assigning  class  labels  to  the 
previously unseen objects. The IF part of a rule is a 
conjunction of feature values and the THEN part is a 
disjunction of class labels. We used the ROSETTA24 
Table 2. Physicochemical descriptors of amino acids used in this study.
no. aaIndex11 code Abbreviation Descriptor
1 RADA880102 e oct-wat. Transfer free energy from octanol to water14
2 FAUJ880103 vdW vol. normalized van der Waals volume15
3 ZIMJ680104 isoel. P Isoelectric point16
4 grAr740102 polarity Polarity17
5 CrAJ730103 freq. turn Normalized frequency of turn18
6 BUrA740101 freq. helix Normalized frequency of alpha-helix19
7 ChAM820102 e sol. wat. Free energy of solution in water20Kierczak et al
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implementation of the rough set theory in order to 
learn a number of IF-THEN rules that associate the 
MCFS-selected  physicochemical  properties  of  the 
amino  acids  of  the  HIV-1  RT  with  the  resistance 
level.
As it is required by the rough sets approach that 
all the features take discrete values, we first applied 
the entropy scaler and the equal frequency binning 
discretization  algorithm.  The  process  of  inferring 
minimal sets of features (reducts) is computationally 
expensive. We used a genetic algorithm, a heuristic 
approach  to  finding  approximate  reducts.  The 
obtained reducts let us infer a number of IF-THEN 
rules  that  link  minimal  combinations  of  amino 
acid properties with a resistance level. In order to 
make  the  model  even  more  general,  we  applied 
a  rule-generalization  algorithm  as  described  by 
Mąkosa.25  In  short,  a  general  rule  is  obtained  by 
merging similar or partially redundant rules and on 
relaxing constraints imposed by them. For instance 
Table 3. Sites selected by the MCFS as significant for resistance to Abacavir (NRTI). Only the top-scoring property is 
presented per site. Prevalence of mutations in the data and MCFs score are reported. 
Rank site property score prevalence status
1 P184 e sol. wat. 104.39 0.57 Known for nrTIs (abacavir, didanosine, 
lamivudine)
*
8 P210 freq. helix 66.11 0.26 Known for nrTIs (abacavir, stavudine, 
tenofovir, zidovudine)
*
12 P41 isoel. point 41.61 0.4 Known for nrTIs (abacavir, didanosine, 
stavudine, tenofovir, zidovudine)
*
16 P215 e oct-wat. 34.39 0.54 Known for nrTIs (abacavir, didanosine, 
stavudine, tenofovir, zidovudine)
*
27 P67 vdW vol. 18.34 0.11 Known for nrTIs (abacavir, stavudine, 
tenofovir, zidovudine)
*
32 P151 freq. turn 14.55 0.04 Known for nrTIs (abacavir, didanosine, 
lamivudine, stavudine, zidovudine)
*
33 P75 vdW vol. 14.12 0.09 Known for other nrTIs (stavudine) +
36 P74 polarity 13 0.11 Known for nrTIs (abacavir, didanosine, 
tenofovir)
*
37 P219 freq. helix 12.79 0.27 Known for other nrTIs (didanosine, 
stavudine, zidovudine)
+
39 P118 e oct-wat. 12.48 0.17 Known but considered unimportant *
41 P44 vdW vol. 12.18 0.1 Known for other nrTIs (tenofovir) +
49 P43 freq. helix 10.61 0.14 Unknown + + +
54 P116 freq. helix 9.77 0.03 Unknown + + +
59 P115 isoel. point 9.36 0.03 Known for nrTIs (abacavir) *
78 P228 e oct-wat. 7.99 0.14 Unknown + + +
79 P65 vdW vol. 7.97 0.04 Known for nrTIs (abacavir, didanosine, 
lamivudine, tenofovir)
*
83 P70 freq. turn 7.6 0.28 Known for nrTIs (didanosine, 
stavudine, tenofovir, zidovudine)
+
86 P135 freq. turn 7.42 0.42 Unknown + + +
87 P181 freq. helix 7.39 0.15 Known for nnrTIs (efavirenz, 
etravirine, nevirapine)
+ +
91 P122 isoel. point 7.28 0.49 Unknown + + +
symbols represent the status of a site: *sites known to contribute to resistance to the particular drug;  +sites where mutations are associated with 
resistance to some nrTI drugs but not to Abacavir; ++sites where mutations contribute to resistance to nnrTI drugs; +++sites that are not included in the 
literature.5,6,30rough set-based model of hIV-1 rT resistome
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the following three rules (abbreviations explained 
in Table 2):
IF P101 polarity ((–∞, 2.100)) AND 
P190 freq. turn ([0.045,∞)) AND P179 
freq.  turn((-∞,  0.70))  THEN  resistant 
toNevirapine
IF  P101  polarity([-1.800,  2.100)) 
AND  P190  freq.  turn([1.40,∞))  THEN 
resistanttoNevirapine
IF  P101  polarity((-∞,  -0.500))  AND 
P190  freq.  turn([0.045,  1.50))  AND 
P179  freq.  turn((-∞,  0.70))  THEN 
resistanttoNevirapine
are  partially  redundant  and  can  be  merged  into 
one rule:
IF P101 polarity ((-∞, 2.100)) AND 
P190 freq. turn ([0.045,∞)) AND P179 
freq.  turn((-∞,  0.70))  THEN  resistant 
toNevirapine
Since the removal of the P179  freq.  turn 
((–∞, 0. 70)) part has very little effect on the 
accuracy  of  the  rule,  further  simplification  can  be 
applied which results in the final rule:
IF P101 polarity ((-∞, 2.100)) AND 
P190  freq.  turn  ((0.045,∞))  THEN 
resistanttoNevirapine
By  using  general  rules  we  minimized  the  risk 
of  overfitting  our  model  to  the  training  data.  The 
ensemble of this rules constitutes a model that can 
be used to predict resistance of new HIV-1 strains. 
Table 4. Sites selected by the MCFS as significant for resistance to Delavirdine (NNRTI). Only the top-scoring property is 
presented per site. Prevalence of mutations in the data and MCFs score are reported. 
Rank site property score prevalence status
1 P151 e oct-wat. 42.48 0.04 Known for nrTIs (abacavir, didanosine, 
lamivudine, stavudine, zidovudine)
*
4 P184 vdW vol. 36.06 0.56 Known for nrTIs (abacavir, didanosine, 
lamivudine)
*
7 P41 isoel. point 35.55 0.4 Known for nrTIs (abacavir, didanosine, 
stavudine, tenofovir, zidovudine)
*
10 P210 e sol. wat. 27.36 0.26 Known for nrTIs (abacavir, stavudine, 
tenofovir, zidovudine)
+
21 P75 freq. helix 22.54 0.09 Known for nrTIs (stavudine) +
26 P215 e oct-wat. 20.15 0.54 Known for nrTIs (abacavir, didanosine, 
stavudine, tenofovir, zidovudine)
*
28 P118 e oct-wat. 18.88 0.17 Known but considered unimportant *
29 P116 freq. helix 18.38 0.03 Unknown + + +
32 P74 polarity 17.36 0.11 Known for nrTIs (abacavir, didanosine, 
tenofovir)
*
58 P65 isoel. point 9.51 0.04 Known for nrTIs (abacavir, didanosine, 
lamivudine, tenofovir)
*
60 P44 e oct-wat. 9.37 0.1 Known for nrTIs (tenofovir) +
64 P67 vdW vol. 7.94 0.11 Known for nrTIs (abacavir, stavudine, 
tenofovir, zidovudine)
+
68 P43 freq. helix 7.27 0.14 Unknown + + +
76 P218 polarity 6.61 0.08 Unknown + + +
83 P228 freq. turn 6.23 0.14 Unknown + + +
85 P219 e sol. wat. 5.95 0.27 Known for nrTIs (didanosine, 
stavudine, zidovudine)
*
86 P211 freq. turn 5.68 0.54 Unknown + + +
Symbols represent the status of a site: *Sites known to contribute to resistance to Delavirdine; +sites where mutations are associated with resistance to some 
NNRTI drugs but not to Delavirdine; ++sites where mutations contribute to resistance to nrTI drugs; +++sites that are not included in the literature.5,6,30Kierczak et al
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Typically all the rules that constitute the model vote 
for the final decision. A threshold defining a minimal 
amount of votes necessary to label an object with a 
decision may result in multiple decisions for the same 
object. We would like to emphasize that the rules used 
by the model are inherently descriptive and can easily 
be  analyzed  by  a  domain  expert.  The  description 
of  the  data  is  presented  in  Table 1.  Table 12 
provides the detailed description of the models.
Validation
The validity of each model was determined in 10-fold 
cross-validation and in the so-called randomization 
test. In addition, the predictive quality of each general 
model was verified using an external test set. First, 
we randomly divided each data set into a training set 
and an external test set. Each training set contained 
80% of the sequences from the original data set and 
the remaining 20% of the sequences constituted the 
external test set. Both the training and the test set had 
the same distribution of the decision class (resistance) 
as  the  original  data.  Subsequently,  we  performed 
10-fold  cross-validation  on  the  training  set.  The 
training data were randomly divided into ten subsets 
of equal size, Di, i = 1, 2, …, 10. We then generated 
ten new training sets of sequences (Ni) by sequentially 
removing  one  of  the  Di  subsets  from  the  original 
training set. Thus, the N1 data set contained all the 
data but the D1 subset, the N2 data set contained all 
the data but the D2 and so forth. Thereafter we used 
each of the Ni training sets to build a rough set-based 
classifier. The classifier was then used to classify the 
objects from the remaining Di subset. Therefore each 
sequence from the original data set was present once 
in a test set and nine times in a training set. In order to 
assess the probability that the obtained results could 
Table 5. Sites selected by the MCFS as significant for resistance to Lamivudine (NRTI). Only the top-scoring property is 
presented per site. Prevalence of mutations in the data and MCFs score are reported. 
Rank site property score prevalence status
1 P184 vdW vol. 407.38 0.56 Known for nrTIs (abacavir, didanosine, 
lamivudine)
*
8 P67 e oct-wat. 25.35 0.11 Known for nrTIs (abacavir, stavudine, 
tenofovir, zidovudine)
+
12 P41 isoel. point 21.62 0.4 Known for nrTIs (abacavir, didanosine, 
stavudine, tenofovir, zidovudine)
+
13 P215 vdW vol. 21.29 0.54 Known for nrTIs (abacavir, didanosine, 
stavudine, tenofovir, zidovudine)
+
18 P75 freq. turn 18.47 0.09 Known for nrTIs (stavudine) +
21 P210 e oct-wat. 16.23 0.26 Known for nrTIs (abacavir, stavudine, 
tenofovir, zidovudine)
+
25 P65 e oct-wat. 14.52 0.04 Known for nrTIs (abacavir, didanosine, 
lamivudine, tenofovir)
*
44 P44 e oct-wat. 9.4 0.1 Known for nrTIs (tenofovir) +
50 P118 e oct-wat. 7.07 0.17 Known but considered unimportant *
51 P228 e oct-wat. 7 0.14 Unknown + + +
57 P83 e sol. wat. 6.03 0.15 Unknown + + +
62 P211 vdW vol. 5.66 0.54 Unknown + + +
64 P70 isoel. point 5.6 0.28 Known for nrTIs (didanosine, 
stavudine, tenofovir, zidovudine)
+
65 P122 vdW vol. 5.58 0.48 Unknown + + +
66 P181 isoel. point 5.57 0.15 Known for nnrTIs (efavirenz, etravirine, 
nevirapine)
+ +
symbols represent the status of a site: *sites known to contribute to resistance to Lamivudine; +sites where mutations are associated with resistance to some 
nrTI drugs but not to Lamivudine; ++sites where mutations contribute to resistance to nnrTI drugs; +++sites that are not included in the literature.5,6,30rough set-based model of hIV-1 rT resistome
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have been generated by random data, we constructed 
additional  1000  data  sets  per  model  by  randomly 
permuting the decision in the original data set. Thus, 
we broke correspondence between the sequence and 
the resistance value. Each of the 1000 randomized 
data sets was evaluated using 10-fold cross-validation. 
Ultimately, we were using all the sequences from the 
original data set to train a rough set-based classifier 
and validated the predictions on the external test set.
The  performance  of  the  models  was  validated 
using  prediction  accuracy  and  the  area  under  the 
ROC (or Receiver Operating Characteristic) curve 
AUC. The accuracy, equal to a fraction of correctly 
classified sequences, was measured by its mean value 
for  the  cross-validated  experiments  and,  finally, 
by its measurement on the external test. The AUC 
was measured by its mean for the cross-validated 
experiments.
For a two-class classification task, the ROC curve 
accounts for an uneven distribution of the decision 
classes  in  the  original  data  set  and  visualizes  the 
behavior of the classifier at different sensitivity to 
Table 6. Sites selected by the MCFS as significant for resistance to Stavudine (NRTI). Only the top-scoring property is 
presented per site. Prevalence of mutations in the data and MCFs score are reported. 
Rank site property score prevalence status
1 P215 e oct-wat. 101.72 0.54 Known for nrTIs (abacavir, didanosine, 
stavudine, tenofovir, zidovudine)
*
3 P210 isoel. point 82.64 0.26 Known for nrTIs (abacavir, stavudine,  
tenofovir, zidovudine)
*
11 P67 vdW vol. 59.61 0.11 Known for nrTIs (abacavir, stavudine,  
tenofovir, zidovudine)
*
14 P41 isoel. point 50.64 0.4 Known for nrTIs (abacavir, didanosine, 
stavudine, tenofovir, zidovudine)
*
27 P151 vdW vol. 26.31 0.04 Known for nrTIs (abacavir, didanosine, 
lamivudine, stavudine, zidovudine)
*
29 P75 polarity 22.94 0.09 Known for nrTIs (stavudine) *
30 P208 isoel. point 22.44 0.1 Unknown + + +
31 P118 freq. helix 22.24 0.17 Known but considered unimportant *
33 P44 e oct-wat. 21.59 0.1 Known for nrTIs (tenofovir) +
35 P69 e oct-wat. 21.02 0.15 Known for nrTIs (abacavir, didanosine, 
lamivudine, stavudine, tenofovir, zidovudine)
*
47 P219 freq. turn 18.15 0.27 Known for nrTIs (didanosine, stavudine, 
zidovudine)
*
48 P70 vdW vol. 17.83 0.28 Known for nrTIs (didanosine, stavudine, 
tenofovir, zidovudine)
*
52 P116 polarity 16.93 0.03 Unknown + + +
60 P43 freq. helix 15.78 0.14 Unknown + + +
94 P218 freq. helix 8.31 0.08 Unknown + + +
96 P228 isoel. point 7.83 0.14 Unknown + + +
100 P203 freq. turn 7.45 0.12 Unknown + + +
101 P122 vdW vol. 7.17 0.48 Unknown + + +
103 P184 e sol. wat. 6.63 0.56 Known for nrTIs (abacavir, didanosine, 
lamivudine)
+
110 P211 polarity 5.9 0.54 Unknown + + +
111 P62 e sol. wat. 5.85 0.05 Part of the multi-nrTi resistance complex.  
Affects all nrTIs except Tenofovir
*
symbols represent the status of a site: *sites known to contribute to resistance to stavudine; +sites where mutations are associated with resistance to some 
nrTI drugs but not to stavudine; ++sites where mutations contribute to resistance to nnrTI drugs; +++sites that are not included in the literature.5,6,30Kierczak et al
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Table 7. Sites selected by the MCFS as significant for resistance to Tenofovir (NRTI). Only the top-scoring property is 
presented per site. Prevalence of mutations in the data and MCFs score are reported. 
Rank site property score prevalence status
1 P215 e oct-wat. 37.66 0.53 Known for nrTIs (abacavir, didanosine, 
stavudine, tenofovir, zidovudine)
*
3 P184 e oct-wat. 26.41 0.49 Known for nrTIs (abacavir, didanosine, 
lamivudine)
+
10 P67 vdW vol. 17.81 0.12 Known for nrTIs (abacavir, stavudine, 
tenofovir, zidovudine)
*
13 P210 isoel. point 15.27 0.29 Known for nrTIs (abacavir, stavudine, 
tenofovir, zidovudine)
*
19 P41 polarity 13.95 0.37 Known for nrTIs (abacavir, didanosine, 
stavudine, tenofovir, zidovudine)
*
27 P75 e oct-wat. 12.04 0.09 Known for nrTIs (stavudine) +
30 P203 freq. turn 10.62 0.15 Unknown + + +
31 P65 isoel. point 10.46 0.06 Known for nrTIs (abacavir, didanosine, 
lamivudine, tenofovir)
*
38 P219 e sol. wat. 9.28 0.31 Known for nrTIs (didanosine, stavudine, 
zidovudine)
+
47 P43 freq. helix 8.09 0.14 Unknown + + +
48 P44 e oct-wat. 8.07 0.11 Known for nrTIs (tenofovir) *
56 P35 polarity 6.93 0.28 Unknown + + +
57 P69 vdW vol. 6.89 0.16 Known for nrTIs (abacavir, didanosine, 
lamivudine, stavudine, tenofovir, zidovudine)
*
58 P101 freq. helix 6.74 0.12 Known for nnrTIs (efavirenz, etravirine, 
nevirapine)
+ +
65 P74 e oct-wat. 6.26 0.16 Known for nrTIs (abacavir, didanosine, 
tenofovir)
*
74 P70 isoel. point 5.85 0.28 Known for nrTIs (didanosine, stavudine, 
tenofovir, zidovudine)
*
77 P200 polarity 5.38 0.31 Unknown + + +
91 P135 polarity 4.71 0.38 Unknown + + +
94 P208 isoel. point 4.64 0.11 Unknown + + +
symbols represent the status of a site: *sites known to contribute to resistance to Tenofovir; +sites where mutations are associated with resistance to some 
nrTI drugs but not to Tenofovir; ++sites where mutations contribute to resistance to nnrTI drugs; +++sites that are not included in the literature.5,6,30
specificity  ratios.  Sensitivity  is  defined  as  a  ratio 
between  true  positive  predictions  and  the  total 
number of positives. Specificity is a ratio between true 
negative predictions and the total number of negative 
examples. The ROC curve is constructed by plotting 
sensitivity  vs.  1-specificity.  The AUC  value  is  an 
integral over the ROC curve. For a perfect binary 
classifier we have AUC = 1.0 whereas for a random 
classifier AUC = 0.5. Since in our case the decision 
takes three distinct resistance values: “susceptible”, 
“moderately resistant” and “resistant”, we provide a 
separate AUC value for each class by treating the two 
remaining classes as one. For instance, to calculate an 
AUC value for the class “susceptible”, we consider 
both the “moderately resistant” and the “resistant” as 
a new “non-susceptible” class.
At last, we used the results of the randomization 
tests to compute a kind of p-values, i.e. the probability 
that the relationships found in the original data arose 
by pure chance. Our computations were based on the 
assumption that the AUCs obtained in the randomization 
test  are  normally  distributed.  The  normality  was rough set-based model of hIV-1 rT resistome
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Table 8. Sites selected by the MCFS as significant for resistance to Zidovudine (NRTI). Only the top-scoring property is 
presented per site. Prevalence of mutations in the data and MCFs score are reported. 
Rank site property score prevalence status
1 P215 polarity 173.43 0.54 Known for nrTIs (abacavir, didanosine, 
stavudine, tenofovir, zidovudine)
*
6 P67 isoel. point 78.24 0.11 Known for nrTIs (abacavir, stavudine, 
tenofovir, zidovudine)
*
11 P41 isoel. point 58.56 0.4 Known for nrTIs (abacavir, didanosine, 
stavudine, tenofovir, zidovudine)
*
19 P210 isoel. point 41.71 0.26 Known for nrTIs (abacavir, stavudine, 
tenofovir, zidovudine)
*
25 P70 isoel. point 28.08 0.28 Known for nrTIs (didanosine, stavudine, 
tenofovir, zidovudine)
*
28 P219 isoel. point 23.91 0.27 Known for nrTIs (didanosine, stavudine, 
zidovudine)
*
37 P75 polarity 18.15 0.09 Known for nrTIs (stavudine) +
46 P184 e oct-wat. 13.69 0.56 Known for nrTIs (abacavir, didanosine, 
lamivudine)
+
48 P69 e oct-wat. 11.88 0.15 Known for nrTIs (abacavir, didanosine, 
lamivudine, stavudine, tenofovir, zidovudine)
*
56 P151 polarity 9.56 0.04 Known for nrTIs (abacavir, didanosine, 
lamivudine, stavudine, zidovudine)
*
57 P228 vdW vol. 9.55 0.14 Unknown + + +
62 P43 freq. helix 8.64 0.14 Unknown + + +
63 P203 freq. turn 8.63 0.12 Unknown + + +
64 P116 vdW vol. 8.2 0.03 Unknown + + +
71 P74 isoel. point 7.29 0.11 Known for nrTIs (abacavir, didanosine, 
tenofovir)
+
72 P44 vdW vol. 7.27 0.1 Known for nrTIs (tenofovir) +
74 P208 isoel. point 7.21 0.1 Unknown + + +
76 P35 freq. turn 7.05 0.28 Unknown + + +
symbols represent the status of a site: *sites known to contribute to resistance to Zidovudine; +sites where mutations are associated with resistance 
to some nrTI drugs but not to Zidovudine;  ++sites where mutations contribute to resistance to nnrTI drugs;  +++sites that are not included in the 
literature.5,6,30
assessed by examining the so-called Q-Q plots and 
applying Shapiro-Wilk test for normality. Subsequently 
we used Student’s t-test to obtain the p-values.
In addition, we compared the performance of our 
models with the performance of their standard decision 
tree-based  counterparts  with  mutations  represented 
by  one-letter  aa  codes.  We  used  J48  algorithm  as 
provided in the WEKA26 suite to derive the decision 
tree models.
Results and Discussion
Application of the Monte Carlo feature selection method 
combined with a rough set-based approach resulted 
in  statistically  sound,  interpretable  and  generative 
rule-based  models  of  the  RT  sequence-resistance 
relationship.  The  models  can  be  used  to  predict 
HIV-1 resistance to six different NRTI drugs and two 
NNRTIs. By representing mutating amino acids in 
terms of physicochemical changes, the models gained 
generality and can be used to predict resistance for 
previously unseen mutants. Let us assume that only 
the following amino acids have been observed at site 
101: A, E, H, K, P, Q, R, S, insertion, and that this 
observation led to the following rule:
IF (polarity at site 101 =  (-∞,  2.100)) 
THEN resistant to NevirapineKierczak et al
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Table 9. Sites selected by the MCFS as significant for resistance to Didanosine (NRTI). Only the top-scoring property is 
presented per site. Prevalence of mutations in the data and MCFs score are reported. 
Rank site property score prevalence status
1 P103 vdW vol. 134.05 0.07 Known for nnrTIs (efavirenz, nevirapine) +
8 P181 freq. turn 50.79 0.15 Known for nnrTIs (efavirenz, etravirine, 
nevirapine)
+
15 P100 e sol. wat. 12.7 0.04 Known for nnrTIs (efavirenz, etravirine, 
nevirapine)
+
21 P211 isoel. point 7.45 0.51 Unknown + + +
22 P101 vdW vol. 6.71 0.09 Known for nnrTIs (efavirenz, etravirine, 
nevirapine)
+
23 P190 Polarity 6.62 0.11 Known for nnrTIs (efavirenz, etravirine, 
nevirapine)
+
26 P74 Polarity 5.61 0.11 Known for nrTIs (abacavir, didanosine, 
tenofovir)
+ +
27 P122 Polarity 5.27 0.44 Unknown + +
28 P219 e oct-wat. 5.26 0.25 Known for nrTIs (didanosine, stavudine, 
zidovudine)
+ +
29 P210 freq. turn 5.09 0.25 Known for nrTIs (abacavir, stavudine, 
tenofovir, zidovudine)
+ +
35 P41 vdW vol. 4.85 0.37 Known for nrTIs (abacavir, didanosine, 
stavudine, tenofovir, zidovudine)
+ +
41 P135 e oct-wat. 4.5 0.39 Unknown + + +
49 P184 freq. helix 4.32 0.53 Known for nrTIs (abacavir, didanosine, 
lamivudine)
+ +
59 P179 polarity 4 0.13 Known for nnrTIs (etravirine) +
63 P43 e oct-wat. 3.97 0.13 Unknown + + +
64 P221 polarity 3.97 0.04 Unknown + + +
68 P188 freq. turn 3.77 0.03 Known for nnrTIs (efavirenz, nevirapine) +
70 P245 freq. turn 3.73 0.32 Unknown + + +
76 P123 e oct-wat. 3.63 0.22 Unknown + + +
87 P67 freq. turn 3.51 0.11 Known for nrTIs (abacavir, stavudine, 
tenofovir, zidovudine)
+ +
90 P207 polarity 3.45 0.24 Unknown + + +
96 P200 freq. helix 3.35 0.29 Unknown + + +
100 P35 Polarity 3.33 0.26 Unknown + + +
105 P228 vdW vol. 3.3 0.13 Unknown + + +
Symbols represent the status of a site: *Sites known to contribute to resistance to Didanosine; +sites where mutations are associated with resistance to some 
NRTI drugs but not to Didanosine; ++sites where mutations contribute to resistance to nnrTI drugs; +++sites that are not included in the literature.5,6,30
Now, if the model is asked to predict whether a newly 
observed mutation to asparagine at site 101 will result 
in drug resistance, the polarity value for asparagine, 
(polarityN = 11.60) will be substituted to the rule and 
the prediction will be “Resistant to NVP”.
At  the  first  step,  each  RT  sequence  was 
represented by 3,920 properties. Application of the 
MCFS led to a significant reduction of this number 
(see Table 3–Table 10). It was already at this point 
that we have discovered that mutations at several, 
previously  unnoticed  sites  contribute  to  drug 
resistance. There are 5 such sites for Abacavir, 5 for 
Didanosine, 4 for Lamivudine, 8 for Stavudine, 6 for 
Tenofovir, 6 for Zidovudine, 10 for Delavirdine and rough set-based model of hIV-1 rT resistome
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Table 10. Sites selected by the MCFS as significant for resistance to Nevirapine (NNRTI). Only the top-scoring property is 
presented per site. Prevalence of mutations in the data and MCFs score are reported. 
Rank site property score prevalence status
1 P103 vdW vol. 77.84 0.08 Known for nnrTIs (efavirenz, nevirapine) *
4 P181 freq. turn 57.5 0.15 Known for nnrTIs (efavirenz, etravirine, 
nevirapine)
*
9 P190 freq. turn 43.42 0.11 Known for nnrTIs (efavirenz, etravirine, 
nevirapine)
*
22 P100 e sol. wat. 9.99 0.04 Known for nnrTIs (efavirenz, etravirine, 
nevirapine)
*
23 P101 freq. helix 9.33 0.09 Known for nnrTIs (efavirenz, etravirine, 
nevirapine)
*
29 P188 vdW vol. 7.95 0.03 Known for nnrTIs (efavirenz, nevirapine) *
34 P211 isoel. point 6.43 0.52 Unknown + + +
35 P379 e oct-wat. 6.33 0.02 Unknown + + +
36 P98 freq. helix 6.21 0.13 Known for nnrTIs (etravirine, nevirapine) *
38 P102 e oct-wat. 6 0.15 Unknown + + +
39 P184 e oct-wat. 5.97 0.53 Known for nrTIs (abacavir, didanosine, 
lamivudine)
+ + 
44 P179 freq. turn 5.66 0.14 Known for nnrTIs (etravirine) +
46 P74 polarity 5.51 0.11 Known for nrTIs (abacavir, didanosine, 
tenofovir)
+ + 
51 P106 freq. turn 5.39 0.04 Known for nnrTIs (efavirenz, etravirine, 
nevirapine)
*
56 P468 e oct-wat. 5.28 0.03 Unknown + + +
63 P357 polarity 4.9 0.06 Unknown + + +
symbols represent the status of a site: *sites known to contribute to resistance to nevirapine; +sites where mutations are associated with resistance to some 
nnrTI drugs but not to nevirapine; ++sites where mutations contribute to resistance to nrTI drugs; +++sites that are not included in the literature.5,6,30
5 for Nevirapine. Apart from these, there are several 
sites  where  mutations  were  previously  associated 
with resistance to some drugs, but our results suggest 
that also resistance to other drugs may be induced 
by them. We speculate that mutations at the newly 
discovered sites may be either directly responsible 
for drug-resistance or may play compensatory role 
by  accompanying  other  drug-resistance  mutations 
and  diminishing  their  negative  effects,  e.g.  the 
decreased replication rate. Table 11 presents sites that 
are included in various sets of rules for predicting 
drug resistance5,6 but were not selected as significant 
by the MCFS method. The missed sites are either 
underrepresented in the data sets or their influence 
on drug-resistance is much weaker than previously 
assumed. This issue has to be investigated further.
Following  the  feature-selection  step,  we  applied 
rough  set  approach  to  build  rule-based  models  of 
HIV-1  resistance  to  drugs.  We  used  two  different 
sets of parameters leading either to very specific or 
to more general rules that underly a model. Prior to 
model-building,  we  excluded  20%  of  the  available 
examples from each data set in order to use them for 
independent validation. We used the remaining data 
for model-construction. We validated our models in 
10-fold  cross-validation  and  used  area  under  ROC 
curve to measure their performance. All the models 
showed good results with accuracy varying from 69% 
for Delavirdine to 89% for Lamivudine when using 
specific sets of rules and from 69% for Delavirdine 
to 88% for Lamivudine when using generalized rules. 
Similarly, the corresponding AUC values were high in 
the majority of the models (cf. Table 12). In some cases, 
e.g. the resistance-to-Nevirapine model that was based 
on general rules, we observed low AUC values for the 
“moderately resistant” class. This may be due to the fact Kierczak et al
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Table 11. sites mentioned in5,6 but not selected as significant by the MCFS method are marked with “X”.
site Drug Description
ABc ddI 3Tc d4T TDF AZT nVp
P62 X X X X X Part of the 69 multi-resistance complex and of the 
151 multi-resistance complex. Included in6 only.
P69 X X X Part of the 69 multi-resistance complex.
P70 X Part of the 69 multi-resistance complex and the 
TAM complex.
P77 X X X X X Part of the 151 multi-resistance complex.
P108 X Included in6 only.
P116 X Part of the 151 multi-resistance complex.
P151 X Part of the 151 multi-resistance complex.
P219 X Part of the 69 multi-resistance complex and the 
TAM complex.
P230 X Included in5 only.
Abbreviations: ABC, abacavir; ddI, didanosine; 3TC, lamivudine; d4T, stavudine; AZT, zidovudine; NVP, nevirapine. Delavirdine is not included in the articles.
that the artificially set threshold values and the arbitrary 
split  into  three  resistance  classes  is  not  completely 
reflected in real mutation patterns. Generalization of 
the rules did not lead to any significant deterioration of 
the classification quality.25 At the same time it reduced 
the number of rules by an order of magnitude. Models 
built on general rules are smaller, less sensitive to 
overtraining and easier to analyze.
Finally,  we  validated  each  model  on  an  external 
test set (20% of the available examples). In addition, 
we compared the performance of our models to the 
standard decision tree-based models. The decision trees 
performed similarly to their rough set-based counterparts 
but at the same time they were less stable. The decision 
tree-based  models  derived  with  no  feature  selection 
step loose generality and an important interpretational 
layer. The results are summarized in Table 12.
We also compared our model based on generalized 
rules with the model described by the domain expert 
rules5  (cf.  Table 13).  For  both  sets  of  rules,  we 
computed coverage and accuracy. In the case of the 
domain expert rules, we could use the entire data sets 
for the computation while in the case of the rough set 
model, we used only the test sets to avoid the possible 
bias caused by the fact that the rules were derived from 
the training data. Therefore for our model, we provide 
only a pessimistic estimates of accuracy and coverage. 
While accurate, expert rules are applicable only to a 
very limited fraction of examples. The generalized 
rules that underlie our model have significantly higher 
coverage.
Importantly, our generalized rules are conjuncts of 
the values (intervals of values) of physicochemical 
properties of amino acids. This allows seeing which 
amino acids fulfill the criteria imposed by a given rule, 
also when such amino acids were not represented in 
the training set. Given the following rule:
IF  P101  polarity  ((-∞,  2.100))  AND  P190 
freq. turn ([0.045,∞)) THEN resistant 
toNevirapine
we  can  easily  find  which  amino  acids  satisfy  the 
conditions and substitute them into the rule:
IF  P101(any  of:  D,E,H,K,N,Q,R)  AND 
P190(any  but:  A,G,N,P,Y)  THEN  resistant 
toNevirapine
Even though asparagine (N) was not observed at 
site 101 in the available data, our general model is able 
to foresee that an occurrence of such a mutation may 
result in the acquisition of resistance. Such an approach 
already proved to be successful in revealing mechanisms 
underlying resistance to protease inhibitors.27
Figure 2 and Figure 3 present an instance of analysis 
of the strongest rules determining resistance to Abacavir 
and  Nevirapine  respectively.  For  more  details  see 
Supplementary Material, Figure S1–S7.
All the remaining sets of rules were included in the 
online supplementary material.rough set-based model of hIV-1 rT resistome
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Detailed  analysis  indicates  that  although  amino 
acids  at  these  newly  discovered  positions  interact 
directly neither with nucleic acid nor with the ABC 
triphosphate  (ABCTP),  the  detected  mutations  may 
disturb  the  complex  network  of  hydrophobic  and 
polar interactions responsible for the stability of the 
tertiary structure. This may lead to subtle structural 
changes in the relative orientation of the domains and 
active site architecture, preventing ABCTP binding in a 
catalytically competent configuration. However, it seems 
that these small structural changes do not prevent the 
ability of a drug-resistant enzyme to incorporate normal 
nucleotides in the catalyzed reaction.
There are 10 sites (98, 100, 101, 103, 106, 108, 
181, 188, 190 and 230) that experts have associated 
with the resistance to Nevirapine. The model finds 
all these important (except the 108 and the 230 site) 
and pinpoints six other sites as significant (102, 211, 
357, 379, 401 and 468). None of these was previously 
associated with resistance. Additionally, sites 74 and 
184 associated so far only with resistance to NRTI 
drugs and site 179 previously connected to resistance 
to the other NNRTI drugs, transpired to play significant 
role in acquiring the resistance to Nevirapine.
Since  the  training  data  does  not  contain  any 
information on the history of treatment, some of the 
newly discovered sites might have emerged as a result of 
the past therapies. For instance, sites 74 and 184 known 
to contribute to resistance to NRTI drugs were selected 
as important to the resistance to Nevirapine which is a 
NNRTI drug. Therefore their role in the resistance to 
Nevirapine should be further investigated.
Similarly,  sites  that  are  often  mutated  in  other 
HIV subtypes28–30 (e.g. 35, 43, 122, 123, 135, 200, 
211) should be treated with caution. While Kearney 
et al28 consider sites 35, 83, 122, 123, 135, 200 and 
211  as  “non-resistance  polymorphic”,  Kantor  and 
Katzenstein29  suggest  that  mutations  at  these  sites 
(in  particular  43  and  211)  may  play  a  significant 
role in drug resistance evolution and increase viral 
fitness. Site 118 that our method selected as important 
to  resistance  to  some  NRTI  drugs  was  previously 
considered important but in 2005 was removed from 
the list of resistance-inducing mutations.31
The remaining sites discovered by our method yet 
not included in the expert rules5,6,30 deserve further 
attention. Indeed, mutations at sites 208, 218 and 228 
have even been previously suspected32 to contribute 
to resistance.
The presented predictive models are derived from 
a large, although limited number of training examples. 
Even  a  very  large  number  of  examples  would 
not  guarantee  that  they  cover  all  possible  sorts  of 
mutations. A particular advantage of rough sets is the 
ability to deal with contradictions. A rule that classifies 
an object to e.g. the “susceptible OR resistant” class 
is actually very useful since it indicates that, with 
the present knowledge, the object can belong any of 
these classes. If such rule has a significant coverage, it 
suggests the directions of further research. This ability 
is  especially  important  in  the  context  of  medical 
applications  where  it  is  more  desirable  to  perform 
additional examination than misclassifying the case.
While  statistically  sound,  our  findings  should 
be subjected to further experimental validation and 
we see them as a navigational aid for clinicians and 
molecular biologists.
conclusion
The presented approach led us to the in silico discovery 
of several previously unknown mutations that contribute 
to resistance to RT inhibitors. Moreover, we discovered 
the exact values of the biochemical properties that 
will lead to resistance. This extends applicability of 
our model to previously unseen cases. Last, but not 
least, this approach can be applied to a wide class 
Table 13. The coverage and the accuracy of the rules. For 
expert rules we compute accuracy and coverage using all 
the  available  examples. The  “moderately  resistant”  cases 
are treated as “resistant”. In the case of rule-based model 
we compute accuracy and coverage using only the test set 
examples. This gives pessimistic assessment of both the 
measures but enables one to avoid possible bias coming from 
the fact that the rules were derived from the training set. The 
underlined value indicate that the classifier was negated.
Drug expert rules5  Rough set 
rule-based model
coverage Accuracy coverage Accuracy
Abacavir 0.29 0.95 0.85 0.58
Delavirdine no rules no rules 0.99 0.67
Didanosine 0.32 0.78 0.99 0.73
Lamivudine 0.58 0.98 1 0.67
nevirapine 0.4 0.99 0.99 0.76
stavudine 0.59 0.78 0.98 0.8
Tenofovir 0.44 0.57 0.73 0.56
Zidovudine 0.58 0.83 0.98 0.71rough set-based model of hIV-1 rT resistome
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Resistant
Rule P41 P43 P44 P67 P70 P74 P75 P118 P151 P181 P184 P210 P215 P219 P228 LHSsu
pport
in wild 
type
M K E D K L V V Q Y M L T K L
1
any,
not:
IMflwy
any
25
2
#Ed
#Vacdg
npst
any
25
3
#Ed
any
any,
not:
Maelqw
DFTY[C
]gknps
w
any
25
4
any any
any,
not: any
#Vaghk
nprst
Wms any
any
25
5
any any #ILMcf
w
any
any,
not:
Wms any
24
6
#AEScd
any,
not:  #
any
not:
IMflw
#Y[C]gn
ps 24
7
gnptv
any any
any
#Vacdg any KRWfy
23
8 any any any,
not:  #
g
npst any KRWfy
any 23
9
any,
not:
Mfhkrw
y
#ADcgn
pstv
Icflw #V
#FIVY[
CL]mw
19
10 any
any,
Icflw #V
any
DFTY[C
]gknps
19
11
y
not:  E
any,
not:
#Vacdg
npst
any ]gknps
w
any
19
12 any,
not:  #
#ADcgn
pstv
#aehkl
mqw any,
not:
Maelqw
any
18
13
any
any Icflw any #Vaghk
nprst 18
14
any
EKdn D
any,
not:
Yfrw IVaghkl
prw Wms
any
18
15 any
#aehkl
mqw #Vacdg
npst
any
DEKn 18
16 any,
not:  # any GKcdnp
swy
ILaghkp Icflw any
#V any
any
Filwy 17
17 EKdn any
g p
r
Icflw any
any,
not:
Maelqw
Wms
any
any 17
Colors correspond to the number of amino acids satisfying the constraint: 
           All amino acids allowed.    
           Less specific rule (10−19 mutations lead to resistance). 
           The most specific rule (up to 10 mutations lead to resistance).
       
Figure 2. The strongest rules determining resistance to Abacavir. Amino acids are encoded using standard one-letter abbreviations. # indicates insertion 
of any type; “AA” is an amino acid observed in the data in the given resistance class; “[AA]” represents an amino acid observed in the data, but in the other 
resistance class and “aa” denotes an amino acid not observed in the data. “LHS support” is a number of examples satisfying the rule.Kierczak et al
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Resistant
Rule P74 P98 P100 P101 P102 P181 P184 P190 P211 LHSsup
port
in wild 
type L A L K K Y M G R
1
any
any 64
2
any
any
any, not: 
# 59
3
any
any
EHKQR
Sdn any
any
any, not: 
any 58
4
any
any, not: 
P#
any Gnpy
any, not: 
# 53
5 L
any
51
6
any, not: 
RQ#en
any
any
48
7 any, not: 
G#
any, not: 
IVY#hhl
mw
any
KR
46
8
any, not: 
G#cden
pqr
any
C any
KR
46
9
any, not: 
C any
DGKRS[
46
10
G#
any
any, not: 
IVY#hhl
mw
Q]ehn
46
11 any
any
any any
any, not: 
EGSdhk
nqr
45
12
any any
#CEQS
Tdfmny 33
13
any Cdfkstw
IMefhklq
rwy
any
32
14
any Cdfkstw
any
any
32
15
C
any, not: 
V#
any
32
16 any, not: 
I#aemv
C
32
Colors correspond to the number of amino acids satisfying the constraint: 
           All amino acids allowed.    
           Less specific rule (10−19 mutations lead to resistance). 
           The most specific rule (up to 10 mutations lead to resistance).
      
Figure 3. The strongest rules determining resistance to nevirapine. Amino acids are encoded using standard one-letter abbreviations. # indicates insertion 
of any type; “AA” is an amino acid observed in the data in the given resistance class; “[AA]” represents an amino acid observed in the data, but in the other 
resistance class and “aa” denotes an amino acid not observed in the data. “LHS support” is a number of examples satisfying the rule.rough set-based model of hIV-1 rT resistome
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of similar problems, such as analysis of influenza 
neuramidase-mutants  resistant  to  drugs,  protein 
engineering or efficient drug design.
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